Puma Biotechnology

Puma Biotech submits NDA to FDA for PB272

Monday, July 25, 2016

Puma Biotechnology, a biopharmaceutical company, has submitted a New Drug Application (NDA) to the FDA for its lead product candidate PB272 (neratinib) for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab (Herceptin)-based therapy.

[Read More]

Foresite closes $100M growth capital fund for late-stage healthcare companies

Friday, February 1, 2013

Foresite Capital Management, a growth equity firm founded by Jim Tananbaum to finance late-stage healthcare companies, has closed its $100 million fund, Foresite Capital Fund I. The firm draws on Tananbaum and his partners’ experience and expertise in building leading healthcare companies, as well as their broad private and public investment experience.

[Read More]

Puma Biotech, Pfizer ink licensing agreement for Nertatinib

Thursday, October 6, 2011

Puma Biotechnology, has signed an agreement with Pfizer to license the worldwide commercial rights to neratinib, a potent, irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases.  Neratinib is being studied in the neoadjuvant, adjuvant and metastatic settings in patients with HER2/ErbB2 positive breast cancer.

[Read More]